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years. 2015 Medicare deductibles and co-insurance rates were used to estimate 
spend for LAAC, acute clinical events and office visits. Average drug costs were 
calculated from the four states with the largest number of Medicare beneficiar-
ies. Patient stay days were taken from HCUP and inpatient rehabilitation prospec-
tive payment system data. Clinical probabilities for LAAC and warfarin were taken 
from PROTECT AF 4-year data and for dabigatran from the RE-LY trial. Results: 
The deductible for the LAAC procedure was $1,260. This compares to an average 
annual acquisition cost of roughly $345 for warfarin and $1,048 for dabigatran. First 
year total costs were $1,734, $1,023 and $1,335, for LAAC, warfarin and dabigatran, 
respectively. By the end of year 2, LAAC was less expensive with total costs of $2,353 
compared to $2,702 (warfarin) and $2,865 (dabigatran). By year 5, LAAC was approxi-
mately half the cost of anticoagulants. ConClusions: Patient out-of-pocket costs 
for stroke prevention in AF are considerable and may represent a burden for many 
Medicare beneficiaries living on fixed incomes. LAAC with the Watchman Device 
provides lifetime stroke prophylaxis without increased bleeding risk at a lower 
cost to patients.
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objeCtives: Bleeding in liver surgery can be difficult to control due to extreme 
vascularity and tissue fragility, including compromised liver (e.g., cancer). Blood 
loss may be minimized with hemostats that have rapid effect and may impact cost 
of care. This study estimated budget impact of using EVARREST vs. SoC in hepatic 
surgery based on two randomized trials. Methods: An economic analysis was 
developed to quantify 30-day cost impact of EVARREST from a U.S. hospital per-
spective. Key resources, from two randomized trials (n=180), included initial treat-
ment, retreatment, operating time, transfusions, ventilator, and hospitalization. 
Transplant patients (n=6) where normal liver tissue was resected were excluded 
from analyses.  SOC was composed mainly of manual compression alone or with 
hemostats. The surgical analysis included resources clinically related to significant 
hemostasis benefits of EVARREST (i.e. retreatment, operating time, transfusion). A 
hospital analysis included all resources collected. Economic analyses were com-
pleted for the following subgroups: abnormal liver, metastatic cancer, anatomic/
non-anatomic liver (classifications using IHPBA definitions), cirrhotic/steatotic liver, 
and if patients were obese or coagulopathic. Published U.S. costs were applied to 
resource use. Analysis results were weighted based on trial size. Results: The 
surgical analysis predicted that the EVARREST cost was offset vs. SoC with a trial-
weighted cost impact of $719 per patient.  The hospital analysis predicted further 
resource reduction with EVARREST with trial-weighted cost-savings of $868 per 
patient.  Subgroup analyses demonstrated a range of results from cost impact to cost 
savings with EVARREST vs. SOC (i.e., $1,976 to -$5,430 per patient, hospital analysis). 
EVARREST use in coagulopathic patients was found to have the largest degree of 
cost savings with $1,859 and $5,176 per patient anticipated, surgical and hospital 
results respectively. ConClusions: In addition to meeting an important unmet 
need in controlling problematic bleeding in liver tissue, this analysis suggests that 
EVARREST can be a cost saving strategy.
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objeCtives: Anti-epidermal growth factor receptor (EGFR) therapies are ineffective 
in tumors with KRAS mutations in exon 2 codons 12 and 13. Thus, guidelines have 
recommended determination of KRAS mutation status in metastatic colorectal can-
cer (mCRC). Both the cobas® KRAS Mutation Test (cobas® test, currently available as 
Research Use Only in the US) and the therascreen KRAS RGQ PCR Kit (therascreen 
test) detect KRAS mutations in exon 2; cobas® test detects twelve mutations and 
therascreen test detects seven mutations in exon 2. We estimated the potential 
clinical and budgetary impact of using the cobas® test versus therascreen test in 
the mCRC setting. Methods: A budget impact model comparing the clinical and 
economic outcomes of using the cobas® test versus therascreen test was devel-
oped from the US payer perspective. We assumed 42,000 annual cases of mCRC 
patients. Model inputs were obtained from literature, whereas testing and treat-
ment costs were calculated from CMS reimbursement rates. KRAS test sensitivity 
reflected the test’s ability to detect mutations in codons 12 and 13; specificity was 
assumed to be the same for both tests. The model calculated the average cost for 
mCRC patients over 5 years, using median time on treatment and median overall 
survival. Based on current practice patterns, the proportion of patients receiving 
KRAS testing before 1st-line, 2nd-line, and 3rd-line therapy were 42%, 32%, and 
26%, respectively. Results: Adopting the cobas® test resulted in a reduction of 289 
patient-months lost due to non-optimal care (i.e. by avoiding anti-EGFR therapies in 
mutant positive patients) and an improvement in median overall survival. Adopting 
the cobas® test generated a total of $2.3 million in cost savings and an average 
decrease of $7 per mCRC patient per month. ConClusions: Using the cobas® test 
with improved sensitivity was associated with a reduction of patient-month lost 
and a decrease of healthcare costs in mCRC patients.
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years, while low risk patients exceeded it in 15 years, respectively. Coexisting risk 
resulted in a sharp increase in the incidence of CRC exceeding the benchmark risk 
in less than 3 years. ConClusions: Intervals based on incidence of CRC diverge 
from adenoma only surveillance recommendations and suggest a longer interval 
of follow-up except for those with co-existing risk.
MEDical DEvicE/DiaGnostics - cost studies
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objeCtives: Depending on the penetration of screening recommendations, it is 
possible that the incidence of detected pulmonary nodules (PNs) could increase 
exponentially in coming years. Currently PN evaluation routinely requires costly 
procedures including imaging, biopsy and surgery. A molecular blood based test that 
measures plasma proteins using selected reaction monitoring mass spectroscopy 
allows for an objective and quantitative assessment of PN benignity. This budget 
impact analysis was performed to quantify the molecular test impact on a US com-
mercial health plan’s direct medical costs. Methods: The budget impact model 
was developed from a commercial health plan perspective, with direct medical costs 
estimated from the MarketScan® reimbursement benchmark data. Total PN diag-
nostic evaluation costs were estimated for a 2-year time horizon and were calculated 
for the current standard of care and care with the introduction of the molecular 
test. Diagnostic procedure resource utilization was obtained from a retrospective 
chart review analysis of a geographically representative sample of indeterminate 
PNs (8-20mm) managed by outpatient pulmonologists. Results: Currently, 52% 
of PNs are evaluated with an invasive procedure (biopsy/surgery) and 48% with 
surveillance alone, with significant cost differences observed between these two 
groups. The base case analysis using a health plan of one million members and a 
rate of 0.25% PNs within the health plan, estimated a 27% reduction in avoidable 
invasive procedures with the introduction of the molecular test. This amounted 
to a total potential cost savings of 20% from procedure and complication avoid-
ance. ConClusions: Adoption of this molecular test may help reduce the number 
of unnecessary invasive procedures being performed for individuals presenting with 
indeterminate pulmonary nodules. The reduced resource utilization can result in 
cost savings for the health plan.
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objeCtives: There is a strong correlation between cardiovascular disease and dia-
betes with management of blood pressure (BP), blood glucose (BG), and lipids being 
essential to preventing disease progression and complications. The FDA-cleared 
Proteus device captures and shares information about medication-taking, rest and 
activity patterns through a mobile device and app, a patch with a wearable sensor 
inside, and sensor-enabled pills. This offering facilitates patient engagement and 
behavioral change, informative provider decision-making, and improvement of out-
comes. An economic model was developed to estimate the impact of reducing BP, 
BG, and lipids via the Proteus offering. Methods: The value of 1-month use of the 
Proteus offering to reduce BP, BG, and lipids was evaluated in patients with comorbid 
hypertension, type 2 diabetes, and hypercholesterolemia from a US payer perspec-
tive for a 1-year time horizon. The clinical and utilization assumptions were derived 
from the literature, expert opinion, and a real-world Proteus study in patients with 
uncontrolled hypertension. Costs were derived from the Medicare Fee Schedule 
and AHRQ databases. Payers were also interviewed for current management of 
these conditions as input to the model. Results: The cost offsets of the Proteus 
service offering were estimated to be $90-185 per month of use, including current 
reimbursement for medications and medication adherence solutions. Medical cost 
savings consisting of reductions in outpatient and inpatient services, monitoring, 
disease management, and medication costs were estimated to be $850-980 per 
patient per year (PPPY), which was mainly driven by a 5-11% reduction in diabetes 
and CVD complications. Revenue opportunities via meeting quality measures pre-
sented an additional value equating to $80-95 PPPY, bringing the total value of the 
Proteus offering to $1020-1260 PPPY. ConClusions: The Proteus offering provides 
opportunities to mitigate the high costs of managing at-risk patients with multiple 
cardiometabolic comorbidities.
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objeCtives: Healthcare costs today are increasingly being shifted from payers to 
patients, yet few providers factor patient costs into treatment decisions. Recent 
advancements in stroke prevention in atrial fibrillation (AF) have resulted in new 
treatment options where previously there were few. While the clinical benefit and 
cost effectiveness of these treatments are supported by a growing body of evi-
dence, the cost impact to patients has not been explored. This analysis sought to 
quantify patient out-of-pocket costs for three stroke prevention strategies: war-
farin, dabigatran and left atrial appendage closure (LAAC) with the Watchman 
Device. Methods: A patient-level budget impact model was used to assess total 
out-of-pocket spend on treatment and treatment-related complications over five 
